Funding Opportunities

Winship researchers receive funding through a variety of awards and grants. View a selection of federal and private funding opportunities for which Winship researchers may be eligible to apply.

The Robert L. "Bobby" Rearden, Jr. Spirit of Winship Award

Winship Cancer Institute created the Bobby Rearden Spirit of Winship Award in memory of a man who embodied all of Winship’s core values and was beloved by all who had the privilege of knowing him.

Gifts from the Bobby Rearden Spirit of Winship Fund support two annual awards to two individuals who exemplify Winship’s culture of caring for patients, including body, mind, and spirit, during and after the patient's cancer journey. One award honors a faculty or staff member and the second honors a volunteer. A monetary award is made in the name of each recipient, to an area of their choosing within Winship, to reward and motivate staff and support Winship’s values of compassion, caring, courage, hope, imagination, translation, and discovery.  

Please help us carry on the spirit of this award by nominating one faculty and one staff member for this honor.

Nomination Form Due Date: Nomination forms may be faxed or emailed to Javana Latimore and must be received by 5pm on Friday, June 23, 2017.

Javana Latimore
Phone: (404) 778-6414
Fax: (404) 778-5048

Stand Up To Cancer Convergence 2.0 Call for Ideas

Stand Up To Cancer (SU2C) is calling for applications to develop data- and computation-intensive collaborations that will advance understanding of the human immune system and cancer immunotherapy.

A letter of intent, listing all members of a team, is required with a 2-3 page description of a project. Collaborative groups of researchers from diverse institutions are preferred. Curriculum vitae and a recent (five year) publication list as well as current funding should be included. Optimally, projects should have a basic science or translational component and propose a small clinical trial to test ideas or early proof of concept. Existing data sets of clinical measurements from immunotherapy trials will be very useful to proposed hypotheses and test ideas, design new algorithms and test them by experiments. Adding components and assays to clinical trials already in progress or planning is acceptable, and this program could augment the clinical trial funding to cover the additions. Projects should be for three to four years. While a budget is not necessary at this time, the scale of a project should not exceed 2.5 million dollars total.

Application Due Date: June 30, 2017

Lung Cancer Research Foundation Grants

The Lung Cancer Research Foundation provides funding for innovative research focused on the prevention, diagnosis, treatment and cure of lung cancer. The maximum award amount is $150,000 for a period of two years. The Foundation encourages applications for projects investigating a wide variety of research topics, focused on one or more of the following areas of lung cancer research:
  • Basic science
  • Translational research
  • Clinical research
  • Supportive care
  • Quality of care/outcomes
Applicants must be affiliated with an academic or research institution in the U.S. or abroad and fall into one of the following categories:
  • Students and fellows
  • Young and mid-career investigators with less than 10 years of experience since initial faculty appointment
  • Non-tenure track researchers, staff scientists, and clinicians

Senior investigators with more than 10 years of experience since faculty appointment are not eligible for LCRF funding but are encouraged to mentor a junior team member through the application process.

Application Due Date: July 1, 2017

International Myeloma Foundation Brian D. Novis Research Award

The International Myeloma Foundation’s Brian D. Novis Research Award are awarded annually to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance) as well as immunoglobulin derived amyloidosis. This year's awards will be $50,000 each for the junior grant and $80,000 for the senior grant.

Junior Grants
The qualifications for a candidate for the Brian D. Novis Junior Research Award include the following:

  • Completed postdoctoral studies or clinical fellowships no later than August 1 of the application year.
  • Ability to devote a minimum of 50% of his or her time to the research project during the Award year.
  • Ability to provide a completed application with evidence of a meritorious research project.
  • NIH, other foundations or similar funding agencies.

Senior Grants
These awards are targeted to established investigators with a track record in myeloma or related disorders, and are designed for projects which represent a different focus, direction, or area of research from those in which they are currently funded. In most cases, these awards will be for pilot projects to obtain sufficient funding for larger applications from NIH or similar larger funding agencies.

The qualifications for a candidate for the Brian D. Novis Senior Research Award include the following:

  • Ability to provide a completed application with evidence of a meritorious research project.
  • NIH, other foundations or similar funding agencies.

Application Due Date: August 1, 2017

NCI R01: HIV/AIDS and the Tumor Niche

The National Cancer Institute of the National Institutes of Health is seeking R01 applications that address the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS).

Application Due Date: August 7, 2017, by 5:00 PM local time of applicant organization

Fanconi Anemia Research Fund Grants

The Fanconi Anemia Research Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control, or cure Fanconi anemia.

Fanconi is interested in supporting interdisciplinary and translational research efforts that effectively address one or more of the following priorities:
  • To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia.
  • To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat, and cure these disorders.
  • To define the pathogenesis of Fanconi anemia-associated cancers, and to develop strategies for prevention, early detection, treatment and cure.
  • To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to maintain a high quality of life.
  • To support the creation of shared resources, databases, and technologies for the international Fanconi anemia research community.

A Letter of Intent (LOI) is required for research funding consideration. The LOI is limited to one page and must include (1) Specific Aims, (2) Lay Abstract, (3) Total Funds Requested and (4) Translatable Applicability. A submitted LOI longer than one page will be returned.

Letter of Intent Due Date: October 13, 2017
Investigator Informed of Decision: November 3, 2017
Grant Submission Due Date: February 2, 2018
Investigator Informed of Decision: June 29, 2018
Earliest Project Start Date: August 1, 2018

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

The Behavioral Research Program, Epidemiology and Genomics Research Program, and Healthcare Delivery Research Program of the National Cancer Institute’s Division of Cancer Control and Population Sciences have collaborated on the release of a program announcement to study the utilization, adherence, and delivery of oral anticancer agents.  Specifically, this program announcement encourages research grant applications to:

  1. Assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; 
  2. Identify structural, systemic, and psychosocial barriers to adherence; and 
  3. Develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.   

PA-17-060 (R01)
PA-17-061 (R21)

Standard application due dates apply.

Cascade Link  TOP